Commentary: Resonance-induced Therapeutic Technique for Skin Cancer Cells

[From Introduction] Basal cell carcinoma (BCC) has the highest occurrence among Non-Melanoma Skin Cancers (NMSC), representing a substantial clinical and economic burden, particularly in regions such as the Southern Hemisphere, where annual treatment costs alone are projected to reach USD 950 million1. An estimated 90,000 non-melanoma and 7000 melanoma skin cancers are diagnosed each year in New Zealand alone, resulting in almost 500 deaths per year2, 3. It poses persistent treatment challenges due to its potential for local invasion and recurrence. Current treatment techniques are either invasive, such as surgery, or they are non-invasive, like gamma radiation, with significant side effects, which include thermal ablation, long recovery periods, and even a breeding ground for second cancer4.